Perrigo announced this week that it has received approvals from the U.S. Food and Drug Administration for Abbreviated New Drug Applications referencing GlaxoSmithKline’s Nicorette White Ice Mint Gum (nicotine polacrilex gum 2 mg and 4 mg). These products will be packaged and marketed as store brands or private brands and provide consumers with high-quality, value alternatives to Nicorette White Ice Mint Gum.
Nicorette White Ice Mint Gum is used to help patients quit smoking by reducing nicotine withdrawal symptoms. Annual sales for the 12 months ending November 2016 were $79 million.
Perrigo’s Executive Vice President & President, Consumer Healthcare Americas, Jeff Needham commented that “This product approval reflects Perrigo’s commitment to providing customers and consumers with high-quality value alternatives to important OTC products. Perrigo’s innovative OTC product offerings are what drive value for our customers as they keep pace with changing consumer preferences.”